Laura Rozan, PhD
About Laura Rozan, PhD
Laura Rozan, PhD, is the Director of WW Commercial Early Assets at Bristol Myers Squibb, with extensive experience in oncology marketing and new product strategy.
Current Position at Bristol Myers Squibb
Laura Rozan, PhD, is presently serving as the Director of WW Commercial Early Assets at Bristol Myers Squibb. Her role involves overseeing the early commercial strategies for new assets in the company's pipeline. Her responsibilities likely encompass market analysis, strategic planning, and alignment with broader commercial and corporate goals.
Previous Experience at Merck
Laura Rozan worked at Merck as the Director of US New Product Strategy in Oncology Marketing from 2019 to 2020. During her 11-month tenure, she was responsible for developing and implementing strategies for new oncology products. Her contributions would have been integral to the marketing and positioning of Merck’s oncology portfolio.
Roles at Celldex Therapeutics
Laura Rozan held multiple roles at Celldex Therapeutics, progressing from Senior Manager to Director in New Product Planning. She served as Senior Manager from 2013 to 2014, Associate Director from 2014 to 2016, and Director from 2016 to 2018. Her work involved strategic planning and the launch of new products, providing valuable expertise to the company's growth and market presence.
Experience at TAIHO ONCOLOGY INC
Laura Rozan was the Director of New Product Planning - Business Development at TAIHO ONCOLOGY INC for 8 months in 2019. In this role, she focused on business development and strategic planning for new products in the oncology sector, contributing to the company’s business growth and market strategies.
Educational Background
Laura Rozan holds a PhD from the University of Michigan, reflecting a robust academic foundation. Additionally, she attended Tufts University, further contributing to her extensive educational background. Her academic achievements have provided a critical foundation for her professional career in life sciences and oncology marketing.